

**UNIVERSITI TEKNOLOGI MARA**

**DEVELOPMENT OF A PCR METHOD FOR DETECTION  
OF *UGT1A1* POLYMORPHISM**

**KHAIRUL MUHAIMIN BIN OTHMAN**

**Dissertation submitted in partial fulfillment of the requirement for the  
degree of Bachelor of Pharmacy (Hons)**

**Faculty of Pharmacy**

**October 2007**

## **ACKNOWLEDGEMENT**

I would like to take this opportunity to express my deepest gratitude to my supervisor, Prof. Dr. Mohd Zaki Salleh, of the Faculty of Pharmacy, Universiti Teknologi MARA for his guidance, advice and instructions right from the first stage of preparation and throughout this research project. If not with his support, encouragement and good advice wherever required it would not have been possible for me to accomplish this study as good as possible. I also would like to wish my appreciation to all postgraduate students in the Pharmacogenomic Research Laboratory especially Miss Hazwanie Hashim who had generously provided her scientific expertise and many helpful suggestions for this project.

Special thanks to Dr. Kalavathy, the coordinator for the Research Instrumentation (PHM 555) course for her continuous support in making this research study a complete success. Lastly, I am indebted to my family for their understanding, enduring patience and support during entire period of my study.

## TABLE OF CONTENTS

	<b>Page</b>
APPROVAL SHEET	
ACKNOWLEDGEMENTS	ii
TABLE OF CONTENTS	iii
LIST OF TABLES	vi
LIST OF FIGURES	vii
LIST OF PLATES	viii
LIST OF ABBREVIATIONS	ix
ABSTRACT	x
CHAPTER ONE (INTRODUCTION)	1
CHAPTER TWO (LITERATURE REVIEW)	3
2.1 Colorectal Cancer	3
2.2 Irinotecan	3
2.2.1 Mechanism of Action	4
2.2.2 Toxicities of Irinotecan	7
2.3 Glucuronidation	8
2.3.1 UDP-Glucuronosyltransferase	8
2.4 Polymorphisms of <i>UGT1A1</i>	9
2.4.1 <i>UGT1A1</i> *6 and <i>UGT1A1</i> *27 Alleles	10
2.4.2 The Importance of Detection for <i>UGT1A1</i> Polymorphism	10

## ABSTRACT

Irinotecan is a camptothecin analog with potent antitumor activity resulting from the inhibition of topoisomerase. Dose-limiting toxicity of irinotecan includes severe leukopenia, neutropenia and diarrhea. Genetic polymorphisms of UDP-glucuronosyltransferase (UGT) 1A1, a key metabolizing enzyme of irinotecan, are important determinants of individual variations in susceptibility to toxicity. Pharmacogenomic studies of irinotecan toxicity have therefore focused on genetic polymorphisms of the *UGT1A1* gene. This project aimed to develop a simple PCR test to identify genetic variants of *UGT1A1* and mainly focus on *UGT1A1*\*6 and *UGT1A1*\*27, single nucleotide polymorphisms in exon 1 of the *UGT1A1* gene that are found mainly in Asian. The allele specific PCR amplification was chosen to be studied because it is suitable for the detection of single nucleotide polymorphism within the gene. In this study, method was optimized only for detection of \*27 allele but not for \*6 allele. Problem with the primer designed for amplification of \*6 allele was thought to be the possible reason for not able to optimize the method for \*6 allele. Pipetting error also could be one of the reason for unsuccessful amplification process. Further study should be carried out to continue this beneficial research. This PCR method can also be commercialized as a tool for individualization of pharmacotherapy especially anti-cancer therapy once the method is fully optimized and validated as it is cost and time saving in patient management due to reduced effort spent in trial and error procedure.

# CHAPTER 1

## INTRODUCTION

Irinotecan is a camptothecin analog with potent antitumor activity resulting from the inhibition of topoisomerase. This anticancer drug is now used widely to treat colorectal, lung and other types of cancers. Dose-limiting toxicity of irinotecan includes severe leukopenia, neutropenia and diarrhea. Genetic polymorphisms of uridine-diphosphate (UDP) glucuronosyltransferase (UGT) 1A1, a key metabolizing enzyme of irinotecan, are important determinants of individual variations in susceptibility to toxicity. Irinotecan is a prodrug that is metabolized by carboxylesterase to its principal active metabolite, SN-38. SN-38 is subsequently conjugated mainly by UGT1A1 to a more polar, inactive glucuronide (SN-38G). Severe toxicity is attributed, at least in part, to increased exposure to SN-38 caused by decreased UGT1A1 activity due to genetic polymorphisms (Ando, 1998).

Pharmacogenomic studies of irinotecan toxicity have therefore focused on genetic polymorphisms of the *UGT1A1* gene, especially *UGT1A1*\*28, a variant sequence in the promoter region. But this research is mainly focus on *UGT1A1*\*6 and *UGT1A1*\*27, single nucleotide polymorphisms in exon 1 of the *UGT1A1* gene. These variants are found mainly in Asians (Araki, 2006). This research aimed to develop a simple PCR test to identify genetic variants of *UGT1A1*. The allele specific PCR amplification was